Immuneering (IMRX)
Develops oral Deep Cyclic Inhibitors for MAPK-pathway-driven cancers.
$5.02
At close+0.17 (+3.61%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions119 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 53.44% | 34.58M shares | |
| Insiders9 holders · as of Jul 16, 2026 | 1.63% | 1.05M shares | |
| Strategic holders1 holder · as of Oct 3, 2025 | 5.64% | 3.65M shares | |
| Otherremainder | ≈ 39.29% | 25.42M shares |
64.70M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (64.70M in the company's Sep 3, 2026 report, 36.30M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
119 holders · 34.58M shares · 39 new positions · 75 increased · 21 reduced · 20 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 9.70M | 15.00% | +6.7K | Aug 13, 2026 |
| BlackRock, Inc. | 4.37M | 6.76% | +2.87M | Aug 7, 2026 |
| Sanofi | 2.71M | 4.19% | 0 | Jul 28, 2026 |
| Vanguard Capital Management LLC | 2.29M | 3.53% | −1.9K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.94M | 2.99% | +106.9K | Aug 14, 2026 |
| Geode Capital Management, LLC | 1.37M | 2.12% | +732.8K | Aug 12, 2026 |
| State Street Corp | 1.00M | 1.55% | +733.5K | Aug 7, 2026 |
| DCF Advisers, LLC | 790.0K | 1.22% | +648.5K | Aug 10, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.50% | 8.79M | 13G | Oct 7, 2025 ↗ |
| BlackRock, Inc. | 6.70% | 4.36M | 13G | Jul 28, 2026 ↗ |
| Benjamin J. Zeskind | 6.60% | 4.36M | 13G | Jan 22, 2026 ↗ |
| HBM Healthcare Investments (Cayman) Ltd. | 5.70% | 3.65M | 13G | Oct 3, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 23, 2026 | Benjamin J. Zeskinddirector, officer: PRESIDENT AND CEO | Purchase | 2,400 | $4.56 | 2,315,252 |
| Jun 15, 2026 | Brett Matthew Hallofficer: CHIEF SCIENTIFIC OFFICER | Purchase | 6,035 | $4.15 | 382,531 |
| Jan 16, 2026 | Harold Eugene Brakewoodofficer: Chief Business Officer | Purchase | 5,250 | $4.76 | 11,050 |
| Jan 15, 2026 | Thomas J. Schalldirector | Purchase | 21,645 | $4.67 | 74,530 |
| Jan 15, 2026 | Brett Matthew Hallofficer: CHIEF SCIENTIFIC OFFICER | Purchase | 2,298 | $4.57 | 376,496 |
| Jan 13, 2026 | Leah R. Neufeldofficer: CHIEF PEOPLE OFFICER | Purchase | 2,626 | $4.15 | 25,970 |
| Jan 12, 2026 | Peter Feinbergdirector | Purchase | 20,000 | $4.35 | 135,441 |
| Oct 3, 2025 | Peter Feinbergdirector | Purchase | 7,500 | $6.67 | 156,766 |
| Oct 1, 2025 | Michael Bookmanofficer: CHIEF LEGAL OFFICER, SECRETARY | Purchase | 1,020 | $6.83 | 4,870 |
| Oct 1, 2025 | Leah R. Neufeldofficer: CHIEF PEOPLE OFFICER | Purchase | 800 | $6.38 | 23,344 |
CongressHouse and Senate disclosures
Not reported.